An experiment was performed to assess the efficacy of an eye drop in preventing “dry eye.” A principal objective measure used to assess efficacy is the tear breakup time (TBUT),
which is reduced in people with dry eye and which the researchers hope will be increased after use of the eye drop.
In the actual study, participants will be randomized to either active drug or placebo, based on a fairly large sample size. However, a pilot study was first performed based on 14 participants. Under protocol A, the participants had their TBUT measured at baseline and were then instructed to not blink their eyes for 3 seconds, after which time the placebo eye drop was instilled. The TBUT was measured again immediately after instillation as well as at 5, 10, and 15 minutes postinstillation, during which time the study participants were in a controlled-chamber environment with low humidity to exacerbate symptoms of dry eye. On 2 other days participants received protocols B and C. Protocol B was identical to protocol A except that participants were told not to blink for 6 seconds prior to drop instillation. Protocol C was identical to protocol A except that participants were told not to blink their eyes for 10 seconds prior to drop instillation. Note that the same participants were used for each protocol and that for each protocol data are available for each of two eyes. Also, for each eye, two replicate measurements were provided.
The data are available in TEAR.DAT with documentation in TEAR.DOC at www.cengagebrain.com. For each protocol, TBUT (in seconds) was measured (1) at baseline (before drop instillation), (2) immediately after drop instillation, (3) 5 minutes after instillation, (4) 10 minutes after instillation, and (5) 15 minutes after instillation.
The standard protocol used in previous clinical studies of TBUT is a 6-second nonblink interval (protocol B). All the following questions concern protocol B data. For this purpose, average TBUT over two replicates and over both eyes to find a summary value for each time period for each participant.
Does the effect of the placebo eye drop change over time after drop instillation? (Hint: Compare mean TBUT at 5, 10, and 15 minutes postinstillation vs. mean TBUT immediately after drop instillation.)
![Check Mark](/static/check-mark.png)
Want to see the full answer?
Check out a sample textbook solution![Blurred answer](/static/blurred-answer.jpg)
Chapter 7 Solutions
WebAssign for Rosner's Fundamentals of Biostatistics, 8th Edition [Instant Access], Single-Term
- An investigator reviewed the medical records of 200 children seen for care at Boston Medical Center in the past year who were between the ages 8 and 12 and identified 40 children with asthma. He also identified 40 children of the same ages who were free of asthma. Each child and their family were interviewed to assess whether there might be an association between certain environmental factors such as exposure to second-hand smoke. This study is an example of a: Case-Control Study Crossover Trial Cohort Study Randomized Control Trialarrow_forwardAcne is a common skin disease that affects most adolescents and can continue into adulthood. A study compared the effectiveness of three acne treatments and a placebo, all in gel form, applied twice daily for 12 weeks. The study's 517 teenage volunteers were randomly assigned to one of the four treatments. Success was assessed as clear or almost clear skin at the end of the 12 week period. The results of the study can be seen in the table below. Using the appropriate statistical test, determine if there is significant evidence that the four treatments perform differently. If so, how do they compare.arrow_forwardThe May 10, 2007 issue of The New England Journal of Medicine describes two large randomized, placebo-controlled trials of a vaccine for HPV-related cancer. HPV is human papillomavirus, the most common form of sexually transmitted infection. For the group of people who received the vaccine, the HPV-related cancer rate was much lower than for those who received a placebo. Which best describes the goal of this study?arrow_forward
- An investigator reviewed the medical records of 200 children seen for care at Boston Medical Center in the past year who were between the ages 8-12 and identified 40 with asthma. He also identified 40 children of the same ages who were free of asthma. Each child and their family were interviewed to assess whether there might be an association between certain environmental factors such as exposure to second hand smoke. This study is an example of a: randomized controlled trial case-control study cohort study crossover trialarrow_forwardThe drug Prevnar is a vaccine meant to prevent bacterial meningitis. A randomized, double-blind clinical trial was conducted. A total of 551 people were surveyed. Where the subjects in Group 1 received Prevnar and the subjects in Group 2 received a control vaccine. 137 of 452 subjects in Group 1 and 31 of 99 subjects in Group 2 experienced drowsiness as a side effect. Can you conclude that there is a significant difference in the proportion of people in group 1 and group 2 experienced drowsiness as a side affect at the 1% significance level?arrow_forwardOne study of cell phones and the risk of brain cancer looked at a group of 469 people who have brain cancer. The investigators then asked about the use of cell phones. Result: “Our data suggest that the use of hand- held cellular phones is not associated with risk of brain cancer. B . Based on this study, can you determine that cellular use does not CAUSE brain cancer? Why or why not?arrow_forward
- Holt Mcdougal Larson Pre-algebra: Student Edition...AlgebraISBN:9780547587776Author:HOLT MCDOUGALPublisher:HOLT MCDOUGALCollege Algebra (MindTap Course List)AlgebraISBN:9781305652231Author:R. David Gustafson, Jeff HughesPublisher:Cengage LearningGlencoe Algebra 1, Student Edition, 9780079039897...AlgebraISBN:9780079039897Author:CarterPublisher:McGraw Hill
![Text book image](https://www.bartleby.com/isbn_cover_images/9780547587776/9780547587776_smallCoverImage.jpg)
![Text book image](https://www.bartleby.com/isbn_cover_images/9781305652231/9781305652231_smallCoverImage.gif)
![Text book image](https://www.bartleby.com/isbn_cover_images/9780079039897/9780079039897_smallCoverImage.jpg)
![Text book image](https://www.bartleby.com/isbn_cover_images/9781938168383/9781938168383_smallCoverImage.gif)